TP53 and breast cancer: First, when the predisposition to HR-HER2+ was evaluated comparing to TNBC, germline variants on TP53 gene showed the highest pooled Odds Ratio (pOR) of developing HR-HER2+ BC among the meta-analyzed genes (pOR: 5.81; 95% CI: 2.70–12.50; n=10,431).